Fintech PR
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
FinancialNewsMedia.com News Commentary
PALM BEACH, FL, Oct. 17, 2023 /PRNewswire/ — Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US multiple myeloma therapeutics market is a growing market due to the increasing prevalence of multiple myeloma and the development of new therapies. The growth of the market is driven by factors such as an aging population, increasing prevalence of multiple myeloma, and advancements in the development of new therapies. The introduction of new therapies such as immunomodulatory drugs (IMiDs) and proteasome inhibitors has revolutionized the treatment of multiple myeloma. A report from Insights10 projected that the U.S. Multiple Myeloma Therapeutics Market was valued at $3.5 Billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 2.5% from 2022 to 2030 and will reach $4.26 Billion in 2030. Active companies in the markets this week include: Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO), Guardant Health, Inc. (NASDAQ: GH), Natera, Inc. (NASDAQ: NTRA), Quest Diagnostics Incorporated (NYSE: DGX), NeoGenomics, Inc. (NASDAQ: NEO).
The report said: “The cost of multiple myeloma therapies is high, and the cost of newer therapies such as monoclonal antibodies and CAR T-cell therapy is even higher. This limits the affordability of these therapies for many patients, leading to barriers in access to treatment. The treatment of multiple myeloma is complex and often requires a combination of therapies, including chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies. This complexity can lead to challenges in treatment planning and management, as well as potential side effects and complications. Many multiple myeloma therapies have adverse side effects, including anemia, fatigue, neuropathy, and gastrointestinal problems. These side effects can impact the quality of life for patients and limit the effectiveness of therapies. Despite significant advancements in the development of new therapies, some patients may not respond to treatment or may develop resistance to therapies. This limits the efficacy of existing therapies and highlights the need for continued research and development of new treatments. The US multiple myeloma therapeutics market is highly regulated, with strict requirements for drug approval and pricing. This can lead to delays in the approval of new therapies and challenges in pricing and reimbursement for existing therapies.”
Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO) BREAKING NEWS: Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved – TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple Myeloma – Telo Genomics Corp. (the “Company” or “Telo”) today announced the launch of its TeloViewSMM to clinicians in the United States.
Combining molecular biology and artificial intelligence, the diagnostic platform performs industry leading 6-factor quantitative analysis of 3D telomeres, the protective end caps of chromosomes.
TeloView has the potential to characterize multiple cancers, identify their current level of genomic instability and therefore predict their progression.
The Company’s initial clinical launch will focus on testing for “Smoldering Multiple Myeloma (SMM)” the precursor for Multiple Myeloma, a blood-based bone marrow cancer. Approximately 50% of patients with SMM will develop full Multiple Myeloma.
The test is available for physicians to order under the SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation) protocol, an observational study intended for oncology/hematology physicians and their staff in the U.S., to gain experience ordering and utilizing the TeloViewSMM assay. SMART follows a positive industry trend toward introducing novel molecular testing tools in an observational construct to efficiently gather information and feedback from clinicians and their teams.
“The commercial launch of our flagship TeloView platform is a major milestone for our Company” stated Telo Genomics’ CEO Kris Weinberg. “I am extremely proud of our entire team who have put forth a tremendous effort over many years in the development of our platform. Our presentations at this year’s International Myeloma Society (“IMS”) annual meeting and the American Society of Clinical Oncology’s annual meeting were received very positively and have generated many leads for our new assay. We are also very active in discussions with platform partners and in the development of new tests in additional applications.”
While the initial launch of TeloViewSMM will be conducted as a single-site CLIA (Clinical Laboratory Improvement Amendments) model, commercial-scale delivery of testing will be accomplished in partnership with large reference labs where FISH and microscopy resources are available and scalable. The company is also developing products and use cases for the biopharma and CRO segment and has an active business development pipeline focused on CDx opportunities and contract research. CONTINUED… Read this full press release and more news for Telo Genomics at: https://www.financialnewsmedia.com/news-telo/
Other recent developments in the markets of note include:
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, recently announced that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is the first blood-only liquid biopsy test commercially available for MRD testing.
Geisinger is providing coverage for the Guardant Reveal test for individuals with stage II or III colorectal cancer after curative treatment (including surgery) to inform physician decisions about post-treatment therapy and to monitor for disease progression, recurrence or relapse. The frequency of testing covered is aligned with monitoring guidelines established by the National Comprehensive Cancer Network for colorectal cancer. It includes the initial ctDNA test 4 to 6 weeks after surgery (or 2 to 4 weeks after completion of systemic therapy) and thereafter every 3 to 6 months for the first two years, and every 6 to 12 months for the following 3 years.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, recently announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 European Society for Medical Oncology (ESMO) Congress, taking place Oct. 20-24 in Madrid, Spain.
Natera and its collaborators will present MRD data in a total of seven abstracts, including a mini-oral and several poster presentations. The mini-oral presentation will feature an updated analysis of more than 2,000 patients from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest and most comprehensive prospective studies of MRD testing in resectable colorectal cancer (CRC). Other presentations will highlight new Signatera data in rectal cancer, appendiceal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and other solid tumors.
Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced that it will report third quarter 2023 financial results on Tuesday, October 24, 2023, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Timeon that day.
The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: “7895081.” The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-945-5759 for domestic callers or 203-369-3502 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 24, 2023 until midnight Eastern Time on November 7, 2023.
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR® assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.
Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare patients within the United States with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The coverage includes patients with a personal history of high-risk stage II/III HR+/HER2- breast cancer, five or more years from diagnosis who presently do not have evidence of disease.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty six hundred dollars for news coverage of the current press releases issued by Telo Genomics Corp. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: [email protected] – +1(561)325-8757
View original content:https://www.prnewswire.co.uk/news-releases/multiple-myeloma-therapeutics-market-expected-to-reach-4-26-billion-in-2030–301958687.html
Fintech PR
Hinojosa obtains a new EcoVadis gold medal with a score greater than 97% of the companies evaluated
- The company has certified the sustainability of its business management with EcoVadis, receiving the third consecutive gold medal
- With 78 points out of 100, Hinojosa has received its best score to date, mostly due to improvements in key areas such as environment, labour practices and human rights
VALENCIA, Spain, Nov. 26, 2024 /PRNewswire/ — Hinojosa Packaging Group has been awarded the EcoVadis gold medal for the third consecutive year, achieving with 78 points out of 100 its highest score to date and being placed in the 97th percentile of the best rated companies. The company has experienced sustained growth since has started in 2020 to certify management and positive impact on sustainability, within this internationally recognised platform.
The EcoVadis evaluation covers a wide range of non-financial management systems, including impact on issues such as environment, labour practices and human rights, ethics and sustainable procurement. Both in environmental area and labour practices & human rights’ area, the company has improved its previous scores by 10 points, reaching, respectively, 90 and 80. Progress in these two areas has enabled Hinojosa to further improve this year the overall score and position itself in the top 3% of all companies.
The improvement in the environmental area is due, among other things, to the validation of the emissions reduction targets and to achieving the Net-Zero Standard in 2050, as part of the SBTi (Science Based Target initiative). Some of the company’s commitments in this area include achieving a 60% reduction in Scope 1 and 2 emissions and a 42% reduction in Scope 3 emissions by 2030, in addition to using 100% of its electricity from renewable sources.
Adding to these commitments to the future, Hinojosa continues to work on a daily basis to ensure that its constant, steady and sustainable growth is guaranteed accordingly to circular economy’s principle. During 2023, the company reduced emissions by 16% compared to the previous year. This outstanding reduction of carbon footprint was also followed by a waste recovery rate over 95% and a 7% increase in the energy used for production from renewable sources, reaching 71% of the total energy used.
Hinojosa’s efforts to generate a positive impact in labour practices and human rights has also been recognised by EcoVadis. The expansion and consolidation of its FP Dual program or the creation of Hinojosa Cathedra together with Universitat Politècnica de València are some of the most relevant initiatives. In addition, the commitment of all company’s employees to comply with the MSH (Hinojosa Safety Model) has led to an almost fifty percent reduction in global occupational injuries.
EcoVadis corporate sustainability ratings assess each company based on its size, location and business area. More than 90,000 companies are rated internationally, receiving scores between 0 and 100 and in case their performance excels, EcoVadis will grant medals. After winning a bronze medal in 2020 and a silver medal in 2021, Hinojosa has now three consecutive gold medals in 2022, 2023 and 2024. Furthermore, thanks to this assessment, the company has received guidance on its strengths and 22 areas for improvement, which allows Hinojosa to focus on sustainability efforts and to develop action plans to improve performance.
About Hinojosa Packaging Group
Hinojosa is a leading company in the design and manufacture of sustainable packaging solutions. With more than 75 years of history, its model is based on the principles of the circular economy.
Thanks to permanent innovation, customer orientation and the pursuit of excellence, the Group has continued to grow, experiencing a significant boost in recent years with its commitment to internationalisation. Today it has 2900 employees and 24 production plants located in Spain, Portugal, France and Italy, combining the strength of a global group with proximity to the territory.
Hinojosa’s commitment – and performance – is to generate a positive impact where it operates, contributing to a greater common well-being. Because it is not only about making the best packaging, but taking care of everything around you.
Photo: https://mma.prnewswire.com/media/2566591/Hinojosa_Packaging_Group.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hinojosa-obtains-a-new-ecovadis-gold-medal-with-a-score-greater-than-97-of-the-companies-evaluated-302315430.html
Fintech PR
FITUR 2025 Promotes Pride in Tourism, a Key Industry for Sustainable Social and Economic Development
Organised by IFEMA MADRID, the International Tourism Trade Fair will be held from January 22 to 26, 2025 with a firm commitment to boosting business and knowledge exchange.
In its 45th edition, FITUR aligns itself with the global challenges of tourism, placing sustainability at the heart of its agenda in order to contribute to solid economic growth.
MADRID, Nov. 26, 2024 /PRNewswire/ — Tourism has reached 790 million international tourists, generating a direct global economic impact of approximately USD 3.4 trillion in the first seven months of 2024, according to UN Tourism statistics. Given this magnitude, the International Tourism Trade Fair, which closed its last edition with more than 250,000 attendees and the participation of 9,000 companies representing 152 countries, aligns itself with the global challenge facing the industry and reinforces its commitment to the promotion of responsible tourism, inviting its professionals to strengthen their pride of belonging.
FITUR, which is holding its next edition from 22 to 26 January, organised by IFEMA MADRID, brings together the global tourism market, placing sustainability at the centre of its programme with the aim of contributing to solid economic growth and showcasing respectful practices with a positive impact that can be replicated to continue improving the quality of tourism activity.
This is precisely the aim of two of its major projects. On the one hand, the FITURNEXT Observatory, FITUR’s platform dedicated to promoting best practices, which has been working all year over the past six editions to identify and analyse initiatives implemented globally by destinations, companies and organisations around an industry challenge. On this occasion, the 2025 Challenge focused on how tourism can contribute to sustainable food management and, after the analysis of nearly 300 proposals, the winners are Sustainable Gastronomic Routes of Extremadura (Spain), Hurtigruten Cruises (Norway) and Too Good To Go (Denmark).
On the other hand, FITUR 4all, the space that for the second consecutive year brings all people with accessibility needs closer to tourist destinations and services in order to promote inclusive tourism. This project, in addition to awarding the best initiatives, will be producing the first Guide to Best Practices in Accessibility in 2025 to encourage commitment to the development and promotion of inclusive tourism worldwide.
Tourism, a lever for economic and social growth with great responsibility
In addition to the purpose of inspiring professionals to adopt sustainable practices that contribute to the protection of nature and local communities, as well as promoting responsible participation in the Fair, FITUR 2025 also aims to increase its professionals’ pride in belonging to a crucial sector that generates a positive impact on economic and social development. In this context, the entire tourism value chain contributes to the generation of employment, the preservation of cultural diversity and historical heritage, the stimulation of investment in infrastructures and services and the promotion of a sustainable development model. Being part of this industry means being at the heart of an activity that, beyond its contribution to economies, creates spaces for exchange and respect, contributing to understanding between cultures, global cooperation and progress.
Therefore, under the slogan -Orgulllosos. Somos turismo’ (Proud. We are tourism), calls on all participants and visitors to participate in this transformation towards a more responsible tourism that brings real and lasting value to the planet and to people.
For more information about FITUR, click HERE
Photo – https://mma.prnewswire.com/media/2563914/FITUR_IFEMA_MADRID.jpg
Logo – https://mma.prnewswire.com/media/2563915/FITUR_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fitur-2025-promotes-pride-in-tourism-a-key-industry-for-sustainable-social-and-economic-development-302313096.html
PASAY CITY, PHILIPPINES, Nov. 26, 2024 /PRNewswire/ — SM Investments Corporation (SM Investments) was recently recognized at the Asia Corporate Excellence and Sustainability Awards 2024 (ACES), earning the titles of Asia’s Most Influential Companies and Top Sustainability Advocates in Asia.
“We are grateful for the recognition and are inspired to continue to work even harder to grow responsibly and sustainably with the communities that we serve,” said Frederic C. DyBuncio, President and Chief Executive Officer of SM Investments.
The ACES Council praised SM Investments for its comprehensive approach to sustainability, which is embedded in all aspects of its operations. They noted, “Their influence extends beyond business operations, as they set benchmarks for sustainability in the Philippines and across Asia. By building integrated communities, fostering partnerships with MSMEs, and prioritizing corporate governance, SM Investments exemplifies leadership that positively impacts not just its stakeholders, but the broader socio-economic landscape.”
The council also highlighted SM Investments’ commitment to renewable energy and its focus on diversity and inclusion within its workforce. The company operates the Philippine Geothermal Production Company, which runs geothermal fields in Tiwi, Albay, and Makban, Quezon, while exploring additional sources across six provinces.
With a workforce exceeding 130,000, SM Investments is notable for its gender diversity, with 63% of its employees being women, and 58% of leadership roles filled by women.
Established in 2014, the ACES Awards aim to showcase the achievements of Asian companies to the global business community, supported by a council of experts in academia, sustainability, and public policy.
About SM Investments Corporation
SM Investments Corporation is one of the leading Philippine companies that is invested in market-leading businesses in retail, banking, and property. It also invests in ventures that capture high growth opportunities in the emerging Philippine economy.
SM’s retail operations are the country’s largest and most diversified, consisting of grocery stores, department stores and specialty retail stores. SM’s property arm, SM Prime Holdings, Inc., is the largest integrated property developer in the Philippines with interests in malls, residences, offices, hotels, and convention centers as well as tourism-related property developments. SM’s interests in banking are in BDO Unibank, Inc., the country’s largest bank, and China Banking Corporation, the fourth largest private domestic bank.
For more information, please visit www.sminvestments.com
Logo – https://mma.prnewswire.com/media/1880730/Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sm-investments-receives-dual-accolades-for-corporate-excellence-and-sustainability-302316340.html
-
Fintech6 days agoFintech Pulse: Industry Updates, Innovations, and Strategic Moves
-
Fintech5 days agoFintech Pulse: Daily Industry Brief – A Dive into Today’s Emerging Trends and Innovations
-
Fintech PR5 days agoTAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
-
Fintech PR6 days agoROLLER Releases 2025 Attractions Industry Benchmark Report, Unveiling Key Trends and Revenue Strategies
-
Fintech7 days agoFintech Pulse: Milestones, Partnerships, and Transformations in Fintech
-
Fintech PR4 days agoAlkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
-
Fintech PR6 days agoThe CfC St. Moritz Announces New Speakers from BlackRock, Binance, Bpifrance, Temasek, PayPal, and More for Upcoming 2025 Conference
-
Fintech PR4 days agoCorinex Ranked Number 331 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™